Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Lønning
Per E
PE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069448:Denosumab; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D053245:RANK Ligand / Q000627:therapeutic use*; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; D000069448:Denosumab